These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12874396)

  • 1. Clinical characteristics of responders to interferon therapy for relapsing MS.
    Waubant E; Vukusic S; Gignoux L; Dubief FD; Achiti I; Blanc S; Renoux C; Confavreux C
    Neurology; 2003 Jul; 61(2):184-9. PubMed ID: 12874396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort.
    Pereira VC; Malfetano FR; Meira ID; Souza LF; Liem AM; Maiolino A; Alves-Leon SV
    Arq Neuropsiquiatr; 2012 Oct; 70(10):774-9. PubMed ID: 23060103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
    Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL; Scott LJ
    CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
    Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
    Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL; Scott LJ
    BioDrugs; 2004; 18(5):343-7. PubMed ID: 15377176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis.
    Prosperini L; Gallo V; Petsas N; Borriello G; Pozzilli C
    Eur J Neurol; 2009 Nov; 16(11):1202-9. PubMed ID: 19538207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
    Prosperini L; Borriello G; De Giglio L; Leonardi L; Barletta V; Pozzilli C
    BMC Neurol; 2011 Feb; 11():26. PubMed ID: 21352517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study.
    Patti F; Penaherrera JN; Zieger L; Wicklein EM
    BMC Neurol; 2021 Aug; 21(1):324. PubMed ID: 34425763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis.
    Uzawa A; Mori M; Hayakawa S; Masuda S; Kuwabara S
    Eur J Neurol; 2010 May; 17(5):672-6. PubMed ID: 20039942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
    Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
    J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
    Cadavid D; Jurgensen S; Lee S
    PLoS One; 2013; 8(1):e53297. PubMed ID: 23308186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis.
    Portaccio E; Zipoli V; Siracusa G; Sorbi S; Amato MP
    Eur Neurol; 2008; 59(3-4):131-5. PubMed ID: 18057899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
    Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
    Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
    Kappos L; Weinshenker B; Pozzilli C; Thompson AJ; Dahlke F; Beckmann K; Polman C; McFarland H; ;
    Neurology; 2004 Nov; 63(10):1779-87. PubMed ID: 15557490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.
    Gobbi C; Meier DS; Cotton F; Sintzel M; Leppert D; Guttmann CR; Zecca C
    BMC Neurol; 2013 Aug; 13():101. PubMed ID: 23915113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon beta treatment for multiple sclerosis: persisting questions.
    Goodkin DE
    Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon beta for secondary progressive multiple sclerosis.
    La Mantia L; Vacchi L; Di Pietrantonj C; Ebers G; Rovaris M; Fredrikson S; Filippini G
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005181. PubMed ID: 22258960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.